Evidence map›Paper›PMID 36523407›Full record

ArticlemedRxiv : the preprint server for health sciences2022

Severe acute infection and chronic pulmonary disease are risk factors for developing post-COVID-19 conditions.

Pritha Ghosh, Michiel J M Niesen, Colin Pawlowski, Hari Bandi, Unice Yoo, Patrick J Lenehan, Praveen Kumar M, Mihika Nadig, Jason Ross, Sankar Ardhanari and 6 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 7 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 6 institutions in 2 countries.

Pritha Ghoshnference Labs, Bengaluru, India.
Michiel J M Niesennference, inc., Cambridge, Massachusetts 02139, USA.
Colin Pawlowskinference, inc., Cambridge, Massachusetts 02139, USA.
Hari Bandinference, inc., Cambridge, Massachusetts 02139, USA.
Unice Yoonference, inc., Cambridge, Massachusetts 02139, USA.
Patrick J Lenehannference, inc., Cambridge, Massachusetts 02139, USA.
Praveen Kumar Mnference Labs, Bengaluru, India.
Mihika Nadignference, inc., Cambridge, Massachusetts 02139, USA.
Jason Rossnference, inc., 18 3rd St. S.W., Rochester MN 55902, USA.
Sankar Ardhanarinference, inc. 2424 Erwin Road, Durham, NC 27705, USA.
John C O'HoroMayo Clinic, Rochester, MN, USA.
A J Venkatakrishnannference, inc., Cambridge, Massachusetts 02139, USA.
Clifford J RosenMaine Medical Center, Portland, ME 04102, USA.
Amalio TelentiVir Biotechnology, inc., San Francisco, CA, USA.
Ryan T HurtMayo Clinic, Rochester, MN, USA.
Venky Soundararajannference Labs, Bengaluru, India.
Nference (United States) · USMayo Clinic in Arizona · USNference (India) · INUniversity of Minnesota Rochester · USMaine Medical Center · USVIR Biotechnology (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Post-COVID-19 conditions, also known as "long COVID", has significantly impacted the lives of many individuals, but the risk factors for this condition are poorly understood. In this study, we performed a retrospective EHR analysis of 89,843 individuals at a multi-state health system in the United States with PCR-confirmed COVID-19, including 1,086 patients diagnosed with long COVID and 1,086 matched controls not diagnosed with long COVID. For these two cohorts, we evaluated a wide range of clinical covariates, including laboratory tests, medication orders, phenotypes recorded in the clinical notes, and outcomes. We found that chronic pulmonary disease (CPD) was significantly more common as a pre-existing condition for the long COVID cohort than the control cohort (odds ratio: 1.9, 95% CI: [1.5, 2.6]). Additionally, long-COVID patients were more likely to have a history of migraine (odds ratio: 2.2, 95% CI: [1.6, 3.1]) and fibromyalgia (odds ratio: 2.3, 95% CI: [1.3, 3.8]). During the acute infection phase, the following lab measurements were abnormal in the long COVID cohort: high triglycerides (mean

Identifiers

PMID36523407
PMCPMC9753786
OpenAlexW4311071841

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.